Measuring the effects of drugs on cancer cells

July 11, 2018, University of Zurich
cancer
Killer T cells surround a cancer cell. Credit: NIH

A new approach established at the University of Zurich sheds light on the effects of anti-cancer drugs and the defense mechanisms of cancer cells. The method makes it possible to quickly test various drugs and treatment combinations at the cellular level.

Cancer cells are cells over which the human body has lost control. The fact that they are transformed body cells makes it all the more difficult to combat them effectively—whatever harms them usually also harms the healthy cells in the body. This is why it is important to find out about the ' particular weaknesses.

In certain types of breast and ovarian , for example, such weakness is caused by mutations in genes that play a role in DNA repair. Treating cancer cells of this kind with a group of newly approved PARP inhibitors makes it difficult for these cells to replicate their DNA, and they ultimately perish. Normal cells, however, can solve such problems using their intact DNA repair machinery.

Effect of drugs observed in thousands of cells

The Department of Molecular Mechanisms of Disease of the University of Zurich uses cancer cell cultures to investigate the exact effects of this new group of drugs. "Our method of fluorescence-based high-throughput microscopy allows us to observe precisely when and how a works in thousands of cells at the same time," explains postdoc researcher Jone Michelena. Her measurements have revealed how PARP inhibitors lock their target protein in an inactive state on the cells' DNA and how this complicates DNA replication, which in turn leads to DNA damage. If this damage is not repaired quickly, the cells can no longer replicate and eventually die.

The new approach enables researchers to analyze the initial reaction of cancer cells to PARP inhibitors with great precision. What's special about the very sensitive procedure is the high number of individual cells that can be analyzed concurrently with high resolution using the automated microscopes at the Center for Microscopy and Image Analysis of UZH. Cancer cells vary and thus react differently to drugs depending on their mutations and the cell cycle phase they are in. The UZH researchers have now found a way to make these differences visible and quantify them precisely.

Rapid and precise testing of cancer cells

Outside of the laboratory, the success of PARP inhibitors and other cancer medication is complicated by the fact that in some patients the cancer returns—after a certain point, the cancer become resistant and no longer respond to the drugs. The high-throughput method employed by UZH researchers is particularly useful for this kind of problem: Cells can be tested in multiple conditions with short turnover times, and specific genes can be eliminated one by one in a targeted manner. Doing so can reveal which cell functions are needed for a certain drug to take effect.

In addition, mechanisms of drug combinations can be analyzed in great detail. In her study, Jone Michelena has already identified such a combination, which inhibits cancer cell proliferation to a significantly higher extent than the combination's individual components by themselves. "We hope that our approach will make the search for strategies to combat cancer even more efficient," says Matthias Altmeyer, head of the research group at the Department of Molecular Mechanisms of Disease at UZH.

Explore further: Scientists identify cause of resistance to breakthrough breast and ovarian cancer drug

More information: Jone Michelena et al, Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance, Nature Communications (2018). DOI: 10.1038/s41467-018-05031-9

Related Stories

Scientists identify cause of resistance to breakthrough breast and ovarian cancer drug

May 10, 2018
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors.

Pancreatic cancer patients with BRCA mutation may benefit from targeted drug

June 15, 2018
A physician-scientist at the University of Arizona Cancer Center investigated a novel treatment for pancreatic cancer patients whose tumors exhibited a harmful genetic mutation.

PARP-1 may be key to effectiveness of PARP inhibitors, and now researchers can image it

April 26, 2018
Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they've also proven they have a ...

Targeting breast cancer through precision medicine

January 9, 2018
University of Alberta researchers have discovered a mechanism that may make cancer cells more susceptible to treatment. The research team found that the protein RYBP prevents DNA repair in cancer cells, including breast cancer.

Targeting cancer by sabotaging the DNA repair seesaw

January 3, 2018
A protein that cancer cells rely on to stave off cell death also helps them regulate DNA repair, researchers at Winship Cancer Institute of Emory University (Winship) have discovered.

Novel combination therapy shown to be effective in ovarian cancer

December 19, 2017
Researchers at The Wistar Institute have found that combining PARP inhibitors, recently approved for the treatment of BRCA-mutant ovarian cancer, with another small molecule inhibitor was effective to treat ovarian cancers ...

Recommended for you

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

Overcoming resistance to a standard chemotherapy drug

July 19, 2018
Despite being studied for decades, the chemotherapy drug cisplatin is revealing new aspects of how it works. Researchers at Winship Cancer Institute of Emory University have identified an enzyme responsible for making tumors ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.